Study of Pembrolizumab Plus Chemotherapy in Advanced Non-Small Cell Lung Cancer

This study evaluates the combination of pembrolizumab (KEYTRUDA) with standard chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The primary goal is to assess overall survival and progression-free survival compared to chemotherapy alone.

Trial Details

NCT ID
NCT05580562
Phase
Phase 3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Locations (sample)
  • Houston, Texas
  • New York, New York
  • Boston, Massachusetts
  • Chicago, Illinois

Key Eligibility Criteria

  • Age 18 years or older
  • Histologically confirmed advanced NSCLC
  • No prior systemic therapy for metastatic NSCLC
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →